GlassScriptPhysician profile
Merin Abraham
NPI 1740755313
$4,487.41
in general payments reported to CMS, 2019-2025
21 companies · $941 in 2025
The $941 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.42 · 2020: $594 · 2021: $734 · 2022: $868 · 2023: $819 · 2024: $518 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $886.07 | 2020-2023 | Omni Surgical System |
| Abbvie INC. | $605.94 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $462.86 | 2020-2022 | |
| Glaukos Corporation | $428.07 | 2023-2025 | Photrexa Viscous and Photrexa, Idose |
| Sun Pharmaceutical Industries INC. | $362.17 | 2020-2024 | Cequa |
| Alcon Vision LLC | $307.54 | 2022-2025 | Dailies Total1, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $197.04 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $195.34 | 2023-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $186.15 | 2020-2023 | Flarex |
| Tarsus Pharmaceuticals, INC. | $137.63 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $128.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $120.95 | 2020-2022 | |
| Oyster Point Pharma, INC. | $113.41 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $101.28 | 2020-2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $70.25 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $54.68 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $50.33 | 2025 | |
| Harrow Eye, LLC | $31.79 | 2024-2025 | Vevye |
| Travere Therapeutics, INC. | $19.77 | 2021 | |
| Biotissue Holdings INC. | $15.46 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merin Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.